Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis.
Lotte S SpekhorstDaphne S BakkerJulia DrylewiczTheo RispensFloris LoeffCeleste M BoesjesJudith L ThijsGeertruida L E RomeijnLaura LomanMarie-Louise SchuttelaarFemke van WijkMarlies de GraafMarjolein de Bruin-WellerPublished in: Allergy (2022)
This study showed that dose reduction was successful in a subgroup of patients with controlled AD by using a patient-centered dosing regimen. These patients showed stable low disease activity and low severity biomarkers over time.
Keyphrases
- atopic dermatitis
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- end stage renal disease
- rheumatoid arthritis patients
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- juvenile idiopathic arthritis
- clinical trial
- patient reported outcomes
- study protocol